Shire PLC (LON:SHP)‘s stock had its “buy” rating restated by analysts at Liberum Capital in a report issued on Friday. They currently have a GBX 5,500 ($71.55) target price on the biopharmaceutical company’s stock. Liberum Capital’s target price indicates a potential upside of 18.24% from the company’s current price.

Several other equities research analysts have also issued reports on the company. Credit Suisse Group AG reissued an “outperform” rating and set a GBX 5,400 ($70.25) price target on shares of Shire PLC in a research report on Wednesday, April 19th. Barclays PLC initiated coverage on Shire PLC in a research report on Wednesday, March 8th. They set an “overweight” rating and a GBX 6,500 ($84.56) price target on the stock. JPMorgan Chase & Co. reissued an “overweight” rating and set a GBX 6,000 ($78.05) price target on shares of Shire PLC in a research report on Monday, March 27th. Berenberg Bank reaffirmed a “buy” rating on shares of Shire PLC in a research report on Wednesday, April 12th. Finally, Goldman Sachs Group Inc reaffirmed a “buy” rating and issued a GBX 6,800 ($88.46) target price on shares of Shire PLC in a research report on Wednesday, May 3rd. One equities research analyst has rated the stock with a sell rating and seventeen have issued a buy rating to the company’s stock. Shire PLC presently has an average rating of “Buy” and an average price target of GBX 6,108.38 ($79.46).

Analyst Recommendations for Shire PLC (LON:SHP)

Shares of Shire PLC (LON:SHP) traded down 1.83% during trading on Friday, hitting GBX 4651.50. 3,658,827 shares of the stock were exchanged. The stock’s market cap is GBX 42.05 billion. Shire PLC has a one year low of GBX 2,707.19 and a one year high of GBX 5,377.00. The stock’s 50 day moving average price is GBX 4,635.06 and its 200 day moving average price is GBX 4,662.20.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/05/26/liberum-capital-reiterates-buy-rating-for-shire-plc-shp.html.

In other news, insider William Burns bought 136 shares of the firm’s stock in a transaction dated Friday, March 31st. The shares were bought at an average price of GBX 4,742 ($61.69) per share, with a total value of £6,449.12 ($8,389.64).

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

12 Month Chart for LON:SHP

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.